Stem definition | Drug id | CAS RN |
---|---|---|
1285 | 25812-30-0 |
Dose | Unit | Route |
---|---|---|
1.20 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.02 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 79.89 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 98 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 21, 1981 | FDA | PFIZER PHARMS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Rhabdomyolysis | 229.49 | 13.78 | 123 | 10236 | 40535 | 56241173 |
Drug hypersensitivity | 71.83 | 13.78 | 157 | 10202 | 275048 | 56006660 |
Blood triglycerides increased | 62.09 | 13.78 | 34 | 10325 | 11643 | 56270065 |
Coronary artery disease | 56.07 | 13.78 | 46 | 10313 | 30750 | 56250958 |
Blood creatine phosphokinase increased | 49.31 | 13.78 | 41 | 10318 | 27911 | 56253797 |
Myocardial infarction | 48.78 | 13.78 | 72 | 10287 | 92798 | 56188910 |
Acute interstitial pneumonitis | 43.16 | 13.78 | 12 | 10347 | 653 | 56281055 |
Cardiac failure congestive | 37.68 | 13.78 | 62 | 10297 | 87658 | 56194050 |
Myalgia | 37.42 | 13.78 | 78 | 10281 | 131947 | 56149761 |
Myopathy | 37.35 | 13.78 | 23 | 10336 | 9789 | 56271919 |
Drug interaction | 35.91 | 13.78 | 102 | 10257 | 209653 | 56072055 |
Cerebrovascular accident | 34.61 | 13.78 | 64 | 10295 | 99206 | 56182502 |
Pancreatitis | 31.27 | 13.78 | 40 | 10319 | 45040 | 56236668 |
Pancreatitis acute | 28.90 | 13.78 | 29 | 10330 | 25095 | 56256613 |
Lip infection | 28.57 | 13.78 | 6 | 10353 | 97 | 56281611 |
Rheumatoid arthritis | 27.99 | 13.78 | 18 | 10341 | 382586 | 55899122 |
Hypertriglyceridaemia | 25.68 | 13.78 | 15 | 10344 | 5801 | 56275907 |
Off label use | 24.96 | 13.78 | 40 | 10319 | 556140 | 55725568 |
Drug intolerance | 24.61 | 13.78 | 9 | 10350 | 264809 | 56016899 |
Blood glucose increased | 24.38 | 13.78 | 47 | 10312 | 75104 | 56206604 |
Diabetes mellitus | 22.26 | 13.78 | 37 | 10322 | 52698 | 56229010 |
Drug ineffective | 20.79 | 13.78 | 93 | 10266 | 918896 | 55362812 |
Synovitis | 19.84 | 13.78 | 3 | 10356 | 161302 | 56120406 |
Tendon rupture | 19.71 | 13.78 | 14 | 10345 | 7556 | 56274152 |
Diabetes mellitus inadequate control | 17.68 | 13.78 | 17 | 10342 | 13963 | 56267745 |
Hyperlipidaemia | 17.42 | 13.78 | 19 | 10340 | 18090 | 56263618 |
Chronic kidney disease | 17.07 | 13.78 | 29 | 10330 | 42027 | 56239681 |
Arthropathy | 16.68 | 13.78 | 8 | 10351 | 200267 | 56081441 |
Infusion related reaction | 16.42 | 13.78 | 9 | 10350 | 208922 | 56072786 |
Microalbuminuria | 16.34 | 13.78 | 5 | 10354 | 381 | 56281327 |
Blood urea increased | 15.85 | 13.78 | 21 | 10338 | 24452 | 56257256 |
Joint swelling | 15.84 | 13.78 | 18 | 10341 | 289782 | 55991926 |
Bursitis | 15.35 | 13.78 | 22 | 10337 | 27560 | 56254148 |
Bronchitis viral | 15.22 | 13.78 | 6 | 10353 | 973 | 56280735 |
Infected bite | 15.18 | 13.78 | 7 | 10352 | 1665 | 56280043 |
Maternal exposure during pregnancy | 15.14 | 13.78 | 8 | 10351 | 189545 | 56092163 |
Angioedema | 14.77 | 13.78 | 27 | 10332 | 41426 | 56240282 |
Transient ischaemic attack | 14.76 | 13.78 | 24 | 10335 | 33553 | 56248155 |
Hypoglycaemia | 14.66 | 13.78 | 32 | 10327 | 55783 | 56225925 |
Hypophagia | 14.58 | 13.78 | 22 | 10337 | 28854 | 56252854 |
Blood creatine phosphokinase MB increased | 14.19 | 13.78 | 6 | 10353 | 1163 | 56280545 |
Granulocytopenia | 14.18 | 13.78 | 10 | 10349 | 5334 | 56276374 |
Wound | 14.15 | 13.78 | 4 | 10355 | 138800 | 56142908 |
Myositis | 14.06 | 13.78 | 12 | 10347 | 8456 | 56273252 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Rhabdomyolysis | 549.65 | 12.94 | 351 | 14429 | 63230 | 31619334 |
Acute kidney injury | 114.80 | 12.94 | 337 | 14443 | 279377 | 31403187 |
Blood creatine phosphokinase increased | 110.31 | 12.94 | 116 | 14664 | 41858 | 31640706 |
Blood triglycerides increased | 107.96 | 12.94 | 71 | 14709 | 13326 | 31669238 |
Myalgia | 99.00 | 12.94 | 149 | 14631 | 77109 | 31605455 |
Coronary artery disease | 73.92 | 12.94 | 99 | 14681 | 45988 | 31636576 |
Myocardial infarction | 61.66 | 12.94 | 152 | 14628 | 113302 | 31569262 |
Blood cholesterol increased | 57.90 | 12.94 | 54 | 14726 | 16839 | 31665725 |
Drug hypersensitivity | 56.07 | 12.94 | 112 | 14668 | 72487 | 31610077 |
Off label use | 52.43 | 12.94 | 51 | 14729 | 347223 | 31335341 |
Polymyositis | 52.34 | 12.94 | 21 | 14759 | 1394 | 31681170 |
Cardiac failure congestive | 47.00 | 12.94 | 110 | 14670 | 79277 | 31603287 |
Drug interaction | 40.38 | 12.94 | 198 | 14582 | 208345 | 31474219 |
Pancreatitis | 37.48 | 12.94 | 63 | 14717 | 35708 | 31646856 |
International normalised ratio increased | 30.46 | 12.94 | 66 | 14714 | 45157 | 31637407 |
Myopathy | 30.27 | 12.94 | 31 | 14749 | 10821 | 31671743 |
Drug ineffective | 28.05 | 12.94 | 93 | 14687 | 395480 | 31287084 |
Thunderclap headache | 27.45 | 12.94 | 6 | 14774 | 43 | 31682521 |
Drug abuse | 25.45 | 12.94 | 5 | 14775 | 87753 | 31594811 |
Hyperglycaemia | 25.44 | 12.94 | 54 | 14726 | 36422 | 31646142 |
Chromaturia | 25.11 | 12.94 | 31 | 14749 | 13267 | 31669297 |
Haemodialysis | 25.00 | 12.94 | 27 | 14753 | 10018 | 31672546 |
Hypertriglyceridaemia | 24.94 | 12.94 | 24 | 14756 | 7774 | 31674790 |
Chronic kidney disease | 23.96 | 12.94 | 54 | 14726 | 37921 | 31644643 |
Granulocytopenia | 23.84 | 12.94 | 21 | 14759 | 6078 | 31676486 |
Blood glucose increased | 23.32 | 12.94 | 72 | 14708 | 61011 | 31621553 |
Drug level below therapeutic | 23.04 | 12.94 | 19 | 14761 | 5029 | 31677535 |
Type 2 diabetes mellitus | 21.03 | 12.94 | 30 | 14750 | 14754 | 31667810 |
General physical health deterioration | 20.34 | 12.94 | 14 | 14766 | 113421 | 31569143 |
Myositis | 19.57 | 12.94 | 25 | 14755 | 11069 | 31671495 |
Angina unstable | 19.39 | 12.94 | 25 | 14755 | 11170 | 31671394 |
Angioedema | 19.23 | 12.94 | 46 | 14734 | 33572 | 31648992 |
Blood glucose decreased | 18.77 | 12.94 | 26 | 14754 | 12445 | 31670119 |
Erosive duodenitis | 18.11 | 12.94 | 10 | 14770 | 1366 | 31681198 |
Product use in unapproved indication | 18.09 | 12.94 | 12 | 14768 | 99159 | 31583405 |
Death | 17.95 | 12.94 | 97 | 14683 | 360472 | 31322092 |
Treatment noncompliance | 17.88 | 12.94 | 38 | 14742 | 25646 | 31656918 |
Hyperlipidaemia | 17.69 | 12.94 | 26 | 14754 | 13134 | 31669430 |
Tricuspid valve incompetence | 17.35 | 12.94 | 21 | 14759 | 8808 | 31673756 |
Lacrimation decreased | 16.72 | 12.94 | 3 | 14777 | 6 | 31682558 |
Pyrexia | 16.67 | 12.94 | 79 | 14701 | 303761 | 31378803 |
Iron deficiency anaemia | 16.37 | 12.94 | 21 | 14759 | 9338 | 31673226 |
Fanconi syndrome | 16.35 | 12.94 | 10 | 14770 | 1652 | 31680912 |
Muscular weakness | 16.25 | 12.94 | 67 | 14713 | 65381 | 31617183 |
Asthenia | 16.22 | 12.94 | 168 | 14612 | 224587 | 31457977 |
Blood creatinine increased | 16.05 | 12.94 | 83 | 14697 | 88995 | 31593569 |
Reversible cerebral vasoconstriction syndrome | 15.60 | 12.94 | 6 | 14774 | 356 | 31682208 |
Pneumonia haemophilus | 15.47 | 12.94 | 6 | 14774 | 364 | 31682200 |
Otitis externa | 15.05 | 12.94 | 8 | 14772 | 1013 | 31681551 |
Interstitial lung disease | 14.93 | 12.94 | 5 | 14775 | 61398 | 31621166 |
Arteriosclerosis coronary artery | 14.86 | 12.94 | 22 | 14758 | 11186 | 31671378 |
Chest pain | 14.63 | 12.94 | 99 | 14681 | 116858 | 31565706 |
Metabolic acidosis | 14.49 | 12.94 | 46 | 14734 | 39531 | 31643033 |
Breast neoplasm | 14.48 | 12.94 | 3 | 14777 | 16 | 31682548 |
Renal tubular necrosis | 14.14 | 12.94 | 25 | 14755 | 14734 | 31667830 |
Coronary artery stenosis | 14.11 | 12.94 | 19 | 14761 | 8851 | 31673713 |
Hyperlactacidaemia | 13.93 | 12.94 | 11 | 14769 | 2739 | 31679825 |
Intentional product use issue | 13.91 | 12.94 | 3 | 14777 | 49344 | 31633220 |
Aortic valve sclerosis | 13.74 | 12.94 | 7 | 14773 | 813 | 31681751 |
Paralysis | 13.70 | 12.94 | 15 | 14765 | 5648 | 31676916 |
Supraventricular tachycardia | 13.33 | 12.94 | 20 | 14760 | 10287 | 31672277 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Rhabdomyolysis | 726.65 | 12.24 | 412 | 20366 | 95348 | 70812318 |
Blood triglycerides increased | 168.85 | 12.24 | 92 | 20686 | 19572 | 70888094 |
Blood creatine phosphokinase increased | 163.84 | 12.24 | 139 | 20639 | 61124 | 70846542 |
Coronary artery disease | 141.05 | 12.24 | 129 | 20649 | 62607 | 70845059 |
Acute kidney injury | 133.47 | 12.24 | 371 | 20407 | 474253 | 70433413 |
Myocardial infarction | 124.19 | 12.24 | 198 | 20580 | 171447 | 70736219 |
Myalgia | 120.54 | 12.24 | 193 | 20585 | 167699 | 70739967 |
Drug hypersensitivity | 85.52 | 12.24 | 217 | 20561 | 262242 | 70645424 |
Cardiac failure congestive | 81.55 | 12.24 | 144 | 20634 | 135313 | 70772353 |
Drug interaction | 76.15 | 12.24 | 265 | 20513 | 381176 | 70526490 |
Off label use | 72.28 | 12.24 | 67 | 20711 | 742993 | 70164673 |
Myopathy | 61.90 | 12.24 | 48 | 20730 | 18564 | 70889102 |
Pancreatitis | 60.69 | 12.24 | 83 | 20695 | 62585 | 70845081 |
Drug ineffective | 52.15 | 12.24 | 125 | 20653 | 939627 | 69968039 |
Polymyositis | 46.53 | 12.24 | 21 | 20757 | 2980 | 70904686 |
Hypertriglyceridaemia | 44.90 | 12.24 | 33 | 20745 | 11778 | 70895888 |
Hyperlipidaemia | 43.97 | 12.24 | 44 | 20734 | 23819 | 70883847 |
Granulocytopenia | 43.33 | 12.24 | 31 | 20747 | 10616 | 70897050 |
Rheumatoid arthritis | 42.79 | 12.24 | 16 | 20762 | 291789 | 70615877 |
Myositis | 37.40 | 12.24 | 35 | 20743 | 17454 | 70890212 |
Hyperglycaemia | 36.63 | 12.24 | 67 | 20711 | 64605 | 70843061 |
Chromaturia | 35.51 | 12.24 | 39 | 20739 | 23489 | 70884177 |
Blood glucose increased | 34.33 | 12.24 | 86 | 20692 | 102896 | 70804770 |
Blood cholesterol increased | 34.18 | 12.24 | 65 | 20713 | 64539 | 70843127 |
International normalised ratio increased | 34.13 | 12.24 | 74 | 20704 | 80652 | 70827014 |
Drug intolerance | 33.71 | 12.24 | 12 | 20766 | 225675 | 70681991 |
Chronic kidney disease | 31.77 | 12.24 | 61 | 20717 | 60996 | 70846670 |
Acute interstitial pneumonitis | 31.63 | 12.24 | 12 | 20766 | 1098 | 70906568 |
Blood creatinine increased | 29.86 | 12.24 | 101 | 20677 | 142900 | 70764766 |
Angioedema | 29.23 | 12.24 | 62 | 20716 | 66548 | 70841118 |
Muscular weakness | 28.26 | 12.24 | 97 | 20681 | 138239 | 70769427 |
Drug abuse | 27.40 | 12.24 | 5 | 20773 | 147251 | 70760415 |
Pancreatitis acute | 27.07 | 12.24 | 48 | 20730 | 45176 | 70862490 |
Treatment failure | 26.59 | 12.24 | 5 | 20773 | 144137 | 70763529 |
Haemodialysis | 26.58 | 12.24 | 29 | 20749 | 17337 | 70890329 |
Cerebrovascular accident | 26.23 | 12.24 | 97 | 20681 | 143373 | 70764293 |
Pyrexia | 26.03 | 12.24 | 91 | 20687 | 606861 | 70300805 |
Renal failure | 25.98 | 12.24 | 117 | 20661 | 188953 | 70718713 |
Angina unstable | 25.13 | 12.24 | 27 | 20751 | 15866 | 70891800 |
Blood glucose decreased | 24.90 | 12.24 | 33 | 20745 | 24126 | 70883540 |
Hypoglycaemia | 24.62 | 12.24 | 72 | 20706 | 94292 | 70813374 |
General physical health deterioration | 24.39 | 12.24 | 20 | 20758 | 236011 | 70671655 |
Joint swelling | 24.31 | 12.24 | 23 | 20755 | 253188 | 70654478 |
Lip infection | 22.70 | 12.24 | 6 | 20772 | 167 | 70907499 |
Infusion related reaction | 22.66 | 12.24 | 15 | 20763 | 197519 | 70710147 |
Lower respiratory tract infection | 22.63 | 12.24 | 3 | 20775 | 111910 | 70795756 |
Acute myocardial infarction | 22.35 | 12.24 | 59 | 20719 | 72828 | 70834838 |
Treatment noncompliance | 21.19 | 12.24 | 44 | 20734 | 46530 | 70861136 |
Coronary artery stenosis | 20.59 | 12.24 | 21 | 20757 | 11623 | 70896043 |
Chest pain | 20.58 | 12.24 | 135 | 20643 | 251125 | 70656541 |
Thunderclap headache | 20.46 | 12.24 | 6 | 20772 | 246 | 70907420 |
Cardiac disorder | 20.19 | 12.24 | 50 | 20728 | 59365 | 70848301 |
Erosive duodenitis | 20.16 | 12.24 | 10 | 20768 | 1752 | 70905914 |
C-reactive protein increased | 20.03 | 12.24 | 4 | 20774 | 110513 | 70797153 |
Renal cyst | 19.93 | 12.24 | 22 | 20756 | 13323 | 70894343 |
Arteriosclerosis coronary artery | 19.64 | 12.24 | 24 | 20754 | 16191 | 70891475 |
Type 2 diabetes mellitus | 19.30 | 12.24 | 41 | 20737 | 44039 | 70863627 |
High density lipoprotein decreased | 19.11 | 12.24 | 13 | 20765 | 4106 | 70903560 |
Product use issue | 18.89 | 12.24 | 15 | 20763 | 179922 | 70727744 |
Hyperkalaemia | 18.59 | 12.24 | 71 | 20707 | 106520 | 70801146 |
Blood urea increased | 18.17 | 12.24 | 41 | 20737 | 45868 | 70861798 |
Metabolic acidosis | 17.76 | 12.24 | 55 | 20723 | 74291 | 70833375 |
Hypophagia | 17.44 | 12.24 | 38 | 20740 | 41532 | 70866134 |
Intervertebral disc displacement | 17.12 | 12.24 | 6 | 20772 | 438 | 70907228 |
Condition aggravated | 16.43 | 12.24 | 67 | 20711 | 427568 | 70480098 |
Tricuspid valve incompetence | 16.34 | 12.24 | 23 | 20755 | 17794 | 70889872 |
Blood creatine phosphokinase MB increased | 16.17 | 12.24 | 10 | 20768 | 2687 | 70904979 |
Fanconi syndrome | 16.12 | 12.24 | 10 | 20768 | 2703 | 70904963 |
Maternal exposure during pregnancy | 15.79 | 12.24 | 7 | 20771 | 115338 | 70792328 |
Coronary artery occlusion | 15.41 | 12.24 | 20 | 20758 | 14325 | 70893341 |
Intentional product use issue | 15.36 | 12.24 | 8 | 20770 | 120134 | 70787532 |
Myoglobinuria | 15.28 | 12.24 | 7 | 20771 | 1028 | 70906638 |
Wound | 15.16 | 12.24 | 5 | 20773 | 98727 | 70808939 |
Carotid artery stenosis | 14.83 | 12.24 | 15 | 20763 | 8221 | 70899445 |
Ischaemic cardiomyopathy | 14.77 | 12.24 | 14 | 20764 | 7090 | 70900576 |
Product complaint | 14.64 | 12.24 | 18 | 20760 | 12213 | 70895453 |
Hypercholesterolaemia | 14.60 | 12.24 | 22 | 20756 | 18095 | 70889571 |
Iron deficiency anaemia | 14.47 | 12.24 | 25 | 20753 | 23047 | 70884619 |
Bursitis | 14.30 | 12.24 | 27 | 20751 | 26646 | 70881020 |
Tendon rupture | 14.29 | 12.24 | 17 | 20761 | 11152 | 70896514 |
Acute coronary syndrome | 14.25 | 12.24 | 23 | 20755 | 20056 | 70887610 |
Alopecia | 13.84 | 12.24 | 23 | 20755 | 198467 | 70709199 |
Diabetes mellitus inadequate control | 13.50 | 12.24 | 24 | 20754 | 22621 | 70885045 |
Diabetes mellitus | 13.48 | 12.24 | 49 | 20729 | 71775 | 70835891 |
Aspartate aminotransferase increased | 13.45 | 12.24 | 73 | 20705 | 126905 | 70780761 |
Peripheral swelling | 13.40 | 12.24 | 31 | 20747 | 236532 | 70671134 |
Erectile dysfunction | 13.17 | 12.24 | 18 | 20760 | 13544 | 70894122 |
Hepatic steatosis | 13.16 | 12.24 | 30 | 20748 | 33783 | 70873883 |
Blindness | 13.06 | 12.24 | 24 | 20754 | 23203 | 70884463 |
Mitral valve incompetence | 13.04 | 12.24 | 26 | 20752 | 26702 | 70880964 |
Asthenia | 12.98 | 12.24 | 197 | 20581 | 457469 | 70450197 |
Otitis externa | 12.71 | 12.24 | 8 | 20770 | 2219 | 70905447 |
Liver function test abnormal | 12.58 | 12.24 | 43 | 20735 | 61103 | 70846563 |
Hyperlactacidaemia | 12.51 | 12.24 | 11 | 20767 | 5061 | 70902605 |
Pneumonia haemophilus | 12.47 | 12.24 | 6 | 20772 | 984 | 70906682 |
Aortic valve sclerosis | 12.41 | 12.24 | 7 | 20771 | 1590 | 70906076 |
Infected bite | 12.37 | 12.24 | 7 | 20771 | 1600 | 70906066 |
Myocardial ischaemia | 12.36 | 12.24 | 24 | 20754 | 24176 | 70883490 |
None
Source | Code | Description |
---|---|---|
ATC | C10AB04 | CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN Fibrates |
FDA CS | M0199111 | PPAR alpha |
FDA MoA | N0000175375 | Peroxisome Proliferator-activated Receptor alpha Agonists |
FDA EPC | N0000175596 | Peroxisome Proliferator Receptor alpha Agonist |
CHEBI has role | CHEBI:35679 | antilipemic drugs |
MeSH PA | D000963 | Antimetabolites |
MeSH PA | D065687 | Cytochrome P-450 CYP2C8 Inhibitors |
MeSH PA | D065607 | Cytochrome P-450 Enzyme Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D000960 | Hypolipidemic Agents |
MeSH PA | D057847 | Lipid Regulating Agents |
MeSH PA | D065606 | Metabolic Side Effects of Drugs and Substances |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypertriglyceridemia | indication | 302870006 | |
Primary Prevention of Coronary Heart Disease | indication | ||
Hypoalphalipoproteinemia | off-label use | 190785000 | |
Primary biliary cirrhosis | contraindication | 31712002 | DOID:12236 |
Disorder of gallbladder | contraindication | 39621005 | DOID:0060262 |
Acute nephropathy | contraindication | 58574008 | |
Leukopenia | contraindication | 84828003 | DOID:615 |
Impaired renal function disorder | contraindication | 197663003 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Calculus in biliary tract | contraindication | 266474003 | |
Anemia | contraindication | 271737000 | DOID:2355 |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Breastfeeding (mother) | contraindication | 413712001 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 5.13 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Peroxisome proliferator-activated receptor alpha | Nuclear hormone receptor | AGONIST | EC50 | 4.23 | IUPHAR | CHEMBL | |||
Transthyretin | Secreted | Kd | 7 | CHEMBL | |||||
Cytochrome P450 2C8 | Enzyme | Ki | 5.74 | WOMBAT-PK | |||||
Lipoprotein lipase | Enzyme | WOMBAT-PK | |||||||
CDGSH iron-sulfur domain-containing protein 1 | Unclassified | Ki | 5.14 | CHEMBL | |||||
Cytochrome P450 2C9 | Enzyme | Ki | 4.52 | WOMBAT-PK | |||||
Fatty acid-binding protein, liver | Unclassified | Ki | 5.73 | CHEMBL |
ID | Source |
---|---|
4018639 | VUID |
N0000146952 | NUI |
D00334 | KEGG_DRUG |
4018639 | VANDF |
C0017245 | UMLSCUI |
CHEBI:5296 | CHEBI |
4TX | PDB_CHEM_ID |
CHEMBL457 | ChEMBL_ID |
DB01241 | DRUGBANK_ID |
D015248 | MESH_DESCRIPTOR_UI |
3463 | PUBCHEM_CID |
3439 | IUPHAR_LIGAND_ID |
3899 | INN_ID |
Q8X02027X3 | UNII |
4719 | RXNORM |
4778 | MMSL |
523 | MMSL |
d00245 | MMSL |
002050 | NDDF |
35282000 | SNOMEDCT_US |
387189002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Lopid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0071-0737 | TABLET, FILM COATED | 600 mg | ORAL | NDA | 18 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9130 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 17 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9707 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 18 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8354 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 15 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8354 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 15 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-569 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 18 sections |
Gemfibrozil | Human Prescription Drug Label | 1 | 16571-784 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 15 sections |
Gemfibrozil | Human Prescription Drug Label | 1 | 16714-101 | TABLET | 600 mg | ORAL | ANDA | 18 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-732 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 17 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24658-260 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 17 sections |
GEMFIBROZIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-128 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-225 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-146 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 17 sections |
GEMFIBROZIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42806-260 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-745 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-745 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
GEMFIBROZIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-921 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
GEMFIBROZIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-921 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-090 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 18 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-772 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 21 sections |
GEMFIBROZIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43602-452 | TABLET | 600 mg | ORAL | ANDA | 10 sections |
Gemfibrozil | Human Prescription Drug Label | 1 | 50090-2450 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 15 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-2902 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
GEMFIBROZIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5808 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
GEMFIBROZIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5808 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-350 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51138-588 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 18 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51655-142 | TABLET | 600 mg | ORAL | ANDA | 9 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51655-143 | TABLET | 600 mg | ORAL | ANDA | 11 sections |
Gemfibrozil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53002-1068 | TABLET | 600 mg | ORAL | ANDA | 11 sections |